Skip to content

Clinical Trials

Academic GI Cancer Consortium (AGICC)

GI Cancer Clinical Trials

Criterium and The Oncology Consortia of Criterium are currently collaborating with our investigators and leading pharmaceutical partners on a number of exciting trials.

The following are clinical trials conducted by AGICC member and affiliate sites. Please click on the link in each listing to view the trial information at

Perioperative Therapy for Resectable Pancreatic Cancer / Ph II
Estimate the R0 resection rate in patients with Resectable Pancreatic Ductal Adenocarcinoma (R-PDAC) as well as those with Resectable Pancreatic Ductal Adenocarcinoma (BR-PDAC) independently in response to neoadjuvant sequential therapy of combination nab-paclitaxel and gemcitabine followed by stereotactic body radiotherapy (SBRT).
Clinical Trial ID NCT02723331

Colorectal-Gastric-Esophageal Cancers / Ph II
Multicenter, single-arm study of oral ceritinib (LDK378) in adult patients with ALK-activated gastrointestinal malignancies
Clinical Trial ID NCT02638909

Pancreatic Cancer / Ph III
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer (ONTRAC)
Clinical Trial ID NCT01360853

Metastatic Colorectal Cancer / Ph II
Dose Finding Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan (as a second treatment)
Clinical Trial ID NCT01116271
See the poster for this trial that was presented at ASCO

Stage IV, Measurable Colorectal Cancer/ Ph II
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
Clinical Trial ID NCT00912743
See the poster for this trial that was presented at ASCO